Atomic-scale view of bacterial proteins offers path to new tuberculosis drugs

February 3, 2017, Rockefeller University
This detailed 3-D map of a cluster of bacterial proteins is yielding new ideas for how to combat multi-resistant tuberculosis. Credit: Laboratory of Molecular Biophysics at the Rockefeller University/eLife

With the first detailed analysis of a cellular component from a close relative of the pathogen that causes tuberculosis, Rockefeller scientists are suggesting strategies for new drugs to curb this growing health problem. Each year, nearly half a million people around the world are infected with mutant TB strains capable of evading existing antibiotics.

The research, conducted by a Rockefeller team led by Elizabeth Campbell, in collaboration with scientists at Memorial Sloan Kettering, focuses on a cluster of interacting proteins called RNA polymerase. Crucial to all cells, this protein machine carries out a fundamental process in which genes within the DNA blueprint are copied into RNA. The RNA polymerase is the target of the antibiotic rifampicin—a lynchpin of modern TB treatment, which relies on a combination of drugs. Some become resistant to rifampicin by acquiring RNA polymerase mutations.

"Now that we can visualize the molecular machinery of the bacteria that the drug targets, we can use a structure-guided approach to better understand how the drug works, how bacteria become resistant to it, and how to potentially improve the drug's action," says Campbell, a senior research associate in Seth Darst's Laboratory of Molecular Biophysics. She is one of the senior authors of a report published in the online journal eLife.

A molecular map

To visualize the structure the researchers used an imaging method known as x-ray crystallography. By crystalizing enzymes and other molecules interacting with each other—essentially freezing them in action—investigators are able to see how they fit together, much like keys fitting into locks. This ability to visualize what's going on can point the way toward more effective drugs, which may be able to latch more securely onto enzymes and other molecules.

"Based on the findings reported in this study," Campbell says, "we're already investigating new compounds with new mechanisms of action that appear to inhibit the rifampicin-resistant version of TB. Our eventual goal is to get them into clinical trials investigating new treatments for TB, including rifampicin-resistant TB."

Rockefeller chemist Sean Brady, who was not directly involved in the study, provided the team with these new compounds. He is now working together with Campbell, Darst, and other colleagues to further develop them into antibiotics and characterize the basis of their activity.

Not all bacteria are alike

It's estimated that up to one-third of the world's population is infected with M. tuberculosis, the bacterium that causes TB. In the study, the researchers worked with a closely related strain called M. smegmatis. "We needed hundreds of liters of cells to get enough of the material to do the crystallization," says Elizabeth Hubin, a former Rockefeller graduate student who carried out much of the work. "M. tuberculosis grows too slowly to be able to collect the volume that's needed, and it's very dangerous to work with in the lab."

But M. smegmatis relies on an RNA polymerase that is almost identical in sequence, structure, and behavior to the M. tuberculosis RNA polymerase, which led to another important finding in the study: The RNA polymerase from Escherichia coli, the bacterium most commonly used in lab research, is not. This means there may be a drawback to relying on E. coli as a model when developing certain types of antibiotics for bacteria that cause TB or other diseases.

"Most of the studies previously done with RNA polymerase were done using E. coli," Campbell says. "We've always assumed that the enzyme works the same way in all bacteria, but our study shows we can't assume what's found in one bacteria applies to all bacteria.

"Every pathogen needs to be studied individually," she adds, "so the field has a lot of work to do."

Explore further: Team unravels mystery of bacteria's antibiotic resistance

More information: Elizabeth A Hubin et al, Structure and function of the mycobacterial transcription initiation complex with the essential regulator RbpA, eLife (2017). DOI: 10.7554/eLife.22520

Related Stories

'Stressed' bacteria become resistant to antibiotics

February 21, 2013

Bacteria become resistant to antibiotics when stressed, finds research published in BioMed Central's open access journal BMC Evolutionary Biology. In particular E. coli grown at high temperatures become resistant to rifampicin.

Research may yield new ways to treat antibiotic-resistant TB

June 27, 2014

Scientists in the United States and India have successfully modified the precursor to one of the drugs used to treat tuberculosis, an important first step toward new drugs that can transcend antibiotic resistance issues that ...

Recommended for you

In colliding galaxies, a pipsqueak shines bright

February 20, 2019

In the nearby Whirlpool galaxy and its companion galaxy, M51b, two supermassive black holes heat up and devour surrounding material. These two monsters should be the most luminous X-ray sources in sight, but a new study using ...

When does one of the central ideas in economics work?

February 20, 2019

The concept of equilibrium is one of the most central ideas in economics. It is one of the core assumptions in the vast majority of economic models, including models used by policymakers on issues ranging from monetary policy ...

Research reveals why the zebra got its stripes

February 20, 2019

Why do zebras have stripes? A study published in PLOS ONE today takes us another step closer to answering this puzzling question and to understanding how stripes actually work.

Correlated nucleons may solve 35-year-old mystery

February 20, 2019

A careful re-analysis of data taken at the Department of Energy's Thomas Jefferson National Accelerator Facility has revealed a possible link between correlated protons and neutrons in the nucleus and a 35-year-old mystery. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.